Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alla Osipchuk

Clinical Nurse Specialist, Adult Health Caldwell, ID Nurse Practitioner

NPI 1891116653 CMS profile 11094106

1825 S Kimball Ave, Caldwell, ID 83605

Open in the dashboard

General payments

$2,282

213 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alla Osipchuk of Caldwell, ID is reported in the CMS Open Payments database as having received $2,282 across 213 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $245 11
2024 General $396 30
2023 General $363 40
2022 General $481 62
2021 General $796 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alla Osipchuk
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Alla Osipchuk were reported at $245. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Alla Osipchuk Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $796 $133 $48–$445 $132
2022 $481 $163 $57–$526 $149
2023 $363 $173 $64–$597 $160
2024 $396 $171 $54–$575 $164
2025 $245 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $1,119 144 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $298 15 payments
  3. Medtronic, Inc. $291 20 payments
  4. AbbVie, Inc. $125 6 payments
  5. Collegium Pharmaceutical, Inc. $114 10 payments
  6. Pfizer Inc. $110 7 payments
  7. Curonix LLC $56 4 payments
  8. SPR Therapeutics, Inc $47 1 payment
  9. Vertex Pharmaceuticals Incorporated $26 1 payment
  10. Saluda Medical Americas, Inc. $24 1 payment
  11. Other $71 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,282 213 payments
Products named General payments · program years 2021–2025
  1. PROCLAIM $598 88 payments
  2. Proclaim IPG $357 34 payments
  3. RELISTOR Gastroenterology $230 11 payments
  4. RELISTOR Gastroenterology $178 10 payments
  5. XTAMPZA $114 10 payments
  6. ETERNA $107 14 payments
  7. QULIPTA $102 5 payments
  8. RESTORE $95 8 payments
  9. INTELLIS $86 7 payments
  10. COLOGUARD DNA CAPTURE REAGENTS $83 5 payments
  11. Other $673 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

2,472

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$149,216

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

42.5%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Relistor Methylnaltrexone Bromide Brand 12 $27,664
Aimovig Autoinjector Erenumab-Aooe Brand 20 $14,927
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 485 $13,219
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 240 $10,287
Pregabalin Generic 140 $8,985
Xtampza Er Oxycodone Myristate Brand 12 $8,957
Movantik Naloxegol Oxalate Brand 19 $8,784
Ajovy Syringe Fremanezumab-Vfrm Brand 11 $7,725
Diclofenac Sodium Generic 19 $7,208
Oxycodone Hcl Generic 177 $5,773

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$30,460

Medicare's payments for the services billed

Medicare patients

118

Average age 69

Services billed

754

79 women, 39 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 74%
High blood pressure 66%
Depression 42%
Diabetes 36%
Chronic kidney disease 26%
Ischemic heart disease 19%
Osteoporosis 16%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $90
$90 12 —
QULIPTA
  • AbbVie, Inc. $28
$28 — —
BOTOX
  • AbbVie, Inc. $18
$18 — —
UBRELVY
  • AbbVie, Inc. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

213 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record